Abstract 8397: Cardiovascular Safety of Caffeine- and Stimulant-Containing Energy Drinks and Dietary Supplements
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.8397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Sai Samayamanthula und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Retail sales of caffeinated energy drinks rose from $9 billion in 2011 to over $20 billion in 2025, alongside a parallel expansion of pre-workout and stimulant-containing supplements. A growing case-report literature describes arrhythmias, myocardial infarction, and sudden cardiac death temporally associated with consumption of these products, often in young patients without conventional risk factors. Because these products are regulated as foods rather than drugs, they fall outside conventional drug pharmacovigilance. We analyzed the FDA CFSAN Adverse Event Reporting System (CAERS), which captures reports on these products but has not been comprehensively analyzed for cardiovascular signals. Hypothesis: Caffeine- and stimulant-containing products are associated with disproportionate reporting of cardiovascular events relative to other orally consumed products.
Methods
Using R, we downloaded the CAERS product-based extract (2017-2025) from openFDA, retaining 28,345 reports in industry codes 29 (Soft Drink/Water), 41 (Coffee/Tea), and 54 (Vit/Min/Prot/Unconv Diet). We identified exposed reports using a curated keyword list applied to product names: caffeine, methylxanthines (theobromine, guarana, yerba mate, green tea/coffee extracts), sympathomimetics (synephrine, yohimbine, ephedra, DMAA, higenamine), and caffeinated brands (e.g. Red Bull, Monster, Bang, Celsius, 5-Hour Energy, Rockstar, Hydroxycut); exclusion patterns removed products marked caffeine- or stimulant-free. The Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) with chi-square, and the lower 2.5 percentile of the Information Component (IC025) were computed for 10 cardiovascular outcomes between exposed and non-exposed reports. A signal required all 3 thresholds (ROR lower 95% CI > 1; PRR ≥ 2 with χ 2 ≥ 4; IC025 > 0) and ≥ 3 exposed cases. We also performed pre-specified sex- and age-stratified analyses.
Results
Among 854 exposed and 27,491 non-exposed reports, 8 of 10 outcomes met all three signal thresholds. Cardiac arrest was the strongest signal (ROR 11.15, 95% CI 6.50-19.11; 18 cases, 7 deaths), followed by myocardial infarction 4.48 (3.02-6.64), ventricular arrhythmia 3.92 (1.38-11.08), palpitations 3.86 (2.96-5.03), supraventricular arrhythmia 2.72 (1.72-4.32), sinus tachycardia 2.75 (2.11-3.58), angina 2.71 (2.05-3.58), and syncope 2.15 (1.53-3.00). Among adults aged 18-34, 5 of 10 outcomes were signal-positive. Signals were present in both sexes for most outcomes.
Conclusions
Caffeine- and stimulant-containing energy drinks and dietary supplements show disproportionate reporting of acute cardiovascular events across multiple statistical methods, with cardiac arrest the strongest signal and findings concentrated in young adults. These results warrant clinical awareness in young consumers and support prospective surveillance.
Zitieren
APA
Samayamanthula, S., Bouras, A., Sporn, K. C., Chetla, N., Grama, P., Chahal, J., & Benavidez, P. (2026). Abstract 8397: Cardiovascular Safety of Caffeine- and Stimulant-Containing Energy Drinks and Dietary Supplements. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8397
Vancouver
Samayamanthula S, Bouras A, Sporn KC, Chetla N, Grama P, Chahal J, et al. Abstract 8397: Cardiovascular Safety of Caffeine- and Stimulant-Containing Energy Drinks and Dietary Supplements. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8397
BibTeX
@article{Samayamanthula2026,
author = {Samayamanthula, Sai and Bouras, Andrew and Sporn, Kyle C and Chetla, Nitin and Grama, Pramod and Chahal, Jasmanet and Benavidez, Pamela},
title = {Abstract 8397: Cardiovascular Safety of Caffeine- and Stimulant-Containing Energy Drinks and Dietary Supplements},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.8397}
}
EUVIMED